| Preview | Issue Date | Title | Author(s) |
| 2021 | Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer | Lin, H.-M.; Mak, B.; Huynh, K.; Kwan, E.M.; Fettke, H.; Tran, B.; Davis, I.D.; Mahon, K.L.; Stockler, M.R.; Briscoe, K.; Marx, G.M.; Du, P.; Yu, J.; Jia, S.; Joshua, A.M.; Azad, A.A.; Butler, L.M.; Meikle, P.J.; Horvath, L.G.; European Society for Medical Oncology Congress (ESMO) (16 Sep 2021 - 21 Sep 2021 : virtual online) |
| 2023 | Circulating ether lipids in prostate cancer | Horvath, L.; Lin, H.-M.; Huynh, K.; Meikle, T.; Joshua, A.M.; Azad, A.; Tan, W.; Butler, L.; Meikle, P.; American Society of Clinical Oncology Annual Meeting (ASCO) (2 Jun 2023 - 6 Jun 2023 : Chicago, IL) |
| 2019 | Enzalutamide with standard first-line therapy in metastatic prostate cancer | Davis, I.D.; Martin, A.J.; Stockler, M.R.; Begbie, S.; Chi, K.N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W.E.; Horvath, L.G.; Joshua, A.M.; Lawrence, N.J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S.A.; Parnis, F.; Parulekar, W.; Pook, D.W.; et al. |
| 2021 | Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP | Stockler, M.R.; Martin, A.J.; Davis, I.D.; Dhillon, H.M.; Begbie, S.D.; Chi, K.N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W.E.; Horvath, L.G.; Joshua, A.M.; Lawrence, N.J.; Marx, G.M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S.A.; Parnis, F.; Parulekar, W.R.; et al. |
| 2022 | Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin | Mak, B.; Lin, H.-M.; Duong, T.; Mahon, K.L.; Joshua, A.M.; Stockler, M.R.; Gurney, H.; Parnis, F.; Zhang, A.; Scheinberg, T.; Wittert, G.; Butler, L.M.; Sullivan, D.; Hoy, A.J.; Meikle, P.J.; Horvath, L.G. |
| 2021 | Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy | Sweeney, C.J.; Martin, A.J.; Stockler, M.R.; Begbie, S.; Chi, K.N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W.E.; Horvath, L.G.; Joshua, A.M.; Lawrence, N.J.; Marx, G.M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S.A.; Parnis, F.; Parulekar, W.; Pook, D.W.; et al. |
| 2020 | Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer) | Scheinberg, T.; Kench, J.; Stockler, M.; Mahon, K.L.; Sebastian, L.; Stricker, P.; Joshua, A.M.; Woo, H.; Thanigasalam, R.; Ahmadi, N.; Centenera, M.M.; Butler, L.M.; Horvath, L.G. |
